Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$4.11 -9.4%	$4.17	$3.35 ▼ $22.00	$106.20M	0.52	85,867 shs	110,538 shs
DARE Dare Bioscience	$2.63 -1.7%	$2.95	$2.56 ▼ $5.64	$23.23M	1.2	37,112 shs	17,169 shs
NLTX Neoleukin Therapeutics	$17.22 -3.0%	$16.91	$2.03 ▼ $14.36	$161.83M	1.11	50,104 shs	92,384 shs
SLS SELLAS Life Sciences Group	$1.71 -3.7%	$1.59	$0.77 ▼ $2.12	$170.13M	2.25	1.59 million shs	876,404 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+9.95%	+15.27%	+26.89%	-37.77%	-76.39%
DARE Dare Bioscience	+4.30%	-8.09%	-7.93%	-7.29%	-49.77%
NLTX Neoleukin Therapeutics	-3.04%	-9.23%	-0.35%	+23.35%	-44.47%
SLS SELLAS Life Sciences Group	+3.51%	+13.46%	-6.35%	+50.00%	+46.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	2.7805 of 5 stars	3.6	3.0	0.0	0.0	1.9	0.8	1.3
DARE Dare Bioscience	1.1962 of 5 stars	3.3	3.0	0.0	0.0	0.6	0.0	0.0
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	0.3635 of 5 stars	0.0	1.0	0.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	448.11% Upside
DARE Dare Bioscience	2.50	Moderate Buy	$12.00	357.14% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest DARE, SLS, NLTX, and CTNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
4/1/2025	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	2.12	N/A	N/A	$7.66 per share	0.54
DARE Dare Bioscience	$10K	2,323.13	N/A	N/A	($0.69) per share	-3.80
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
SLS SELLAS Life Sciences Group	$1M	170.12	N/A	N/A	$0.13 per share	13.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
DARE Dare Bioscience	-$4.05M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-8.14%	8/11/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest DARE, SLS, NLTX, and CTNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/13/2025	Q1 2025	DARE Dare Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
3/31/2025	Q4 2024	DARE Dare Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	21.47	21.47
DARE Dare Bioscience	N/A	0.56	0.56
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
SLS SELLAS Life Sciences Group	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
DARE Dare Bioscience	6.70%
NLTX Neoleukin Therapeutics	52.37%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
DARE Dare Bioscience	4.00%
NLTX Neoleukin Therapeutics	1.58%
SLS SELLAS Life Sciences Group	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
DARE Dare Bioscience	30	8.85 million	8.50 million	Not Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
SLS SELLAS Life Sciences Group	10	99.78 million	98.58 million	Not Optionable

DARE, SLS, NLTX, and CTNM Headlines

Recent News About These Companies

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 25 at 12:55 AM | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24 at 7:54 PM | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23 at 1:01 PM | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short Interest

June 16, 2025 | marketbeat.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

Nostrand Robert L. Van Acquires 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 13, 2025 | marketbeat.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

Insider Buying: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Purchases 20,000 Shares of Stock

June 3, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Bought by Brooklyn FI LLC

May 28, 2025 | marketbeat.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.com

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.com

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

April 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE, SLS, NLTX, and CTNM Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$4.11 -0.43 (-9.38%)

As of 11:41 AM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Dare Bioscience NASDAQ:DARE

$2.62 -0.05 (-1.69%)

As of 11:38 AM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Neoleukin Therapeutics NASDAQ:NLTX

$17.22 -0.54 (-3.04%)

As of 06/23/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

SELLAS Life Sciences Group NASDAQ:SLS

$1.70 -0.07 (-3.67%)

As of 11:42 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time